Sample size re-estimation without un-blinding for time-to-event outcomes in oncology clinical trials

Sample size re-estimation is essential in oncology studies. However, the use of blinded sample size reassessment for survival data has been rarely reported. Based on the density function of the exponential distribution, an expectation-maximization (EM) algorithm of the hazard ratio was derived, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Li-Hong, Bai, Jian-Ling, Yu, Hao, Chen, Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial Department of Journal of Biomedical Research 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5956254/
https://www.ncbi.nlm.nih.gov/pubmed/28630393
http://dx.doi.org/10.7555/JBR.31.20160111

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5956254/
https://www.ncbi.nlm.nih.gov/pubmed/28630393
http://dx.doi.org/10.7555/JBR.31.20160111

Ejemplares similares